---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-026256"
form_type: "8-K"
ticker: "PLSE"
cik: "0001625101"
company_name: "PULSE BIOSCIENCES, INC."
filed_at: "2026-08-06T20:06:49+00:00"
generated_at: "2026-08-06T20:08:10.362724+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Pulse Biosciences Q2 net loss $24.7M; NANOPULSE-AF enrollment ahead of schedule

## Summary
- Q2 revenue $0.4M; GAAP net loss ($24.7M) vs ($19.2M) year ago; non-GAAP net loss ($19.4M).
- Cash $101.6M at June 30, 2026; raised $46.8M net via ATM in Q2, plus $10.7M post-quarter.
- NANOPULSE-AF pivotal study surpassed 82 evaluable patients; enrollment target raised to 164, completion expected early Q4.
- New $75M ATM facility in place; shelf registration for additional $125M provides financing flexibility.
- Soft tissue revenue $434k, sequential growth; PRECISE-BTN study to complete enrollment within month.

## SEC filing metadata
- accession: 0001437749-26-026256
- form_type: 8-K
- ticker: PLSE
- cik: 0001625101
- company_name: PULSE BIOSCIENCES, INC.
- filed_at: 2026-08-06T20:06:49+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1625101/000143774926026256/0001437749-26-026256-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1625101/000143774926026256/plse20260518_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-026256
- JSON: https://secwatch.observer/filing/0001437749-26-026256.json
- Plain text: https://secwatch.observer/filing/0001437749-26-026256.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.